Head-to-head comparison of [⁶⁸Ga]Ga-P16-093 and 2-[¹⁸F]FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study.

Abstract

This pilot study was prospectively designed to evaluate and compare the diagnostic value of PET/CT using a PSMA-specific tracer [⁶⁸Ga]Ga-P16-093 and a glucose metabolism probe 2-[¹⁸F]FDG in clear cell renal cell carcinoma (ccRCC) patients. Forty-two pathologically confirmed ccRCC patients were included. Within 1 week, each patient underwent [⁶⁸Ga]Ga-P16-093 and 2-[¹⁸F]FDG PET/CT. In addition to visual analysis of tumor number, the standardized uptake value (SUV) was measured for semiquantitative comparison and correlation analysis. For primary ccRCC patients, [⁶⁸Ga]Ga-P16-093 PET/CT demonstrated a significantly higher detection rate (19/22 vs. 13/22, P = 0.031) and higher tumor uptake (15.7 ± 9.0 vs. 5.1 ± 3.4, P < 0.001) than 2-[¹⁸F]FDG PET/CT. In addition, the SUVmax of the primary tumor on [⁶⁸Ga]Ga-P16-093 and 2-[¹⁸F]FDG PET/CT was significantly correlated with pT stage (for [⁶⁸Ga]Ga-P16-093, r = 0.550, P = 0.008; for 2-[¹⁸F]FDG, r = 0.514, P = 0.014) and WHO/ISUP grade (for [⁶⁸Ga]Ga-P16-093, r = 0.566, P = 0.006; for 2-[¹⁸F]FDG, r = 0.492, P = 0.020), respectively. For metastatic ccRCC patients, [⁶⁸Ga]Ga-P16-093 PET/CT also demonstrated a better detection rate (21/22 vs. 14/22, P = 0.008) and higher tumor uptake (11.0 ± 6.4 vs. 4.4 ± 2.7, P < 0.001) than 2-[¹⁸F]FDG PET/CT. The SUVmax on [⁶⁸Ga]Ga-P16-093 PET/CT had a significant association with PSMA expression in primary ccRCC (r = 0.776, P < 0.001) and metastatic ccRCC (r = 0.626, P = 0.029). [⁶⁸Ga]Ga-P16-093 PET/CT demonstrates significantly better tumor detectability than 2-[¹⁸F]FDG PET/CT for ccRCC patients. ⁶⁸Ga-P16-093 and ¹⁸F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients (NCT05432947, Registered 27 June 2021, retrospectively registered) URL OF REGISTRY: https://clinicaltrials.gov/ct2/show/NCT05432947 .